If you are speaking at or hosting a small animal CPD event in 2019, please email details to press@vetsurgeon.org for it to be considered for addition to this list.
This list includes events from CPD Solutions, Improve International, the Veterinary Poisons Information Service and the Small Animal Medicine Society.
Intervet/Schering-Plough Animal Health has launched Posatex (1% Orbifloxacin, 0.1% Mometasone Furoate Monohydrate and 0.1% Posaconazole, Otic Suspension), a new once-a-day treatment for otitis externa in dogs.
Posatex combines an antibacterial, an anti-inflammatory and an antifungal medication in one, seven-day treatment which the company describes as the 'next generation' treatment for severe otitis externa in dogs, designed to make compliance easier and bring fast relief to dogs suffering from this painful condition.
Allan Weingarten, Director, Pharmaceutical Research, and Posatex R&D Project Leader, said: "As every dog owner knows, this is a 'nightmare' disease. As experts in otic products, we feel a special responsibility to keep improving medications and continuing to make the course of treatment more effective, quicker and easier for both dogs and their caregivers. The novel triazole antifungal posaconazole, new to animal health, is the latest example of innovation in this product area."
Posatex Otic Suspension, available in 7.5, 15 and 30g plastic bottles, is indicated for the treatment of otitis externa associated with susceptible strains of yeast (Malassezia pachydermatis) and bacteria (coagulase positive staphylococci, Pseudomonas aeruginosa and Enterococcus faecalis).
According to the company, posaconazole, the newest element in the three-in-one combination, has been shown to be particularly effective against Malassezia pachydermatis and more potent than other veterinary antifungals. Mometasone furoate monohydrate is a potent and safe anti-inflammatory and Orbifloxacin is a broad-spectrum antibiotic with proven efficacy against bacteria.
Ceva Animal Health UK has launched a new Galastop iPhone application to calculate the optimal date for spaying in order to reduce the risk of post-operative false pregnancy.
Enter the end of oestrus date (when the last season finished), and the app will calculate when to spay, i.e. 16 weeks later.
Ceva says it is important not to spay a bitch during a false pregnancy as post-operative chronic pseudopregnancy may develop, which can last longer and be more resistant to standard treatment. However, some cases of false pregnancy can be silent and difficult to detect. Product manager at Ceva Animal Health UK, Fraser Broadfoot MRCVS, said: "It is commonly recommended to wait until 12 weeks after the end of oestrus before spaying. However, silent pseudopregnancy can still occur at this stage so, to be on the safe side, many specialists are now recommending spaying later at 16 weeks after the end of oestrus."
Click here for more details, and to download the app in iTunes.
For further information, please contact your Ceva Animal Health UK representative or call the veterinary support team on 01494 781510.
Sporimune is the first ciclosporin oral solution to be licensed for use in both cats and dogs.
In cats with allergic dermatitis, ciclosporin has proved to be an effective alternative to prednisolone1 Dechra says it has a long-term safety record for chronic treatment of canine atopic dermatitis and remains one of the most important tools within a multi-modal strategy.
Sporimune is available with two dosing syringes per bottle – one for cats and one for dogs – that are graduated in body weight and ml.
There are three bottle sizes to allow for flexibility in dispensing and broached bottles last six months.
Dechra Brand Manager Claire Morgan said: "We are delighted to be able to introduce this popular and effective treatment for cats.
"Allergic skin disease can be challenging to diagnose and manage effectively for both owners and vets, with around 20 per cent of all small animal consultations involving skin conditions.
"Sporimune is a key component of a multi-modal approach involving guidance on allergen and flare factor avoidance and improving skin and coat hygiene to minimise clinical signs and the effects on quality of life for both animal and owner."
Reference
Kaminox contains potassium gluconate and B-vitamins to help dogs affected by hypokalaemia.
Originally released as an oral liquid supplement, Vetplus says this new powdered formulation offers a more concentrated level of potassium for larger pets or those that require a higher dose.
Kaminox sachets are sold in packs of 30, with a scoop provided for easy administration.
Meanwhile, the liquid supplement is available in 60ml and 120ml bottles.
www.vetplus.co.uk/products
Dechra Brand Manager Craig Sankey said: "It can be a very worrying time for owners if their pet is being investigated for, or diagnosed with, hypothyroidism and the new website aims to help them understand more about the condition, how it manifests itself and what they can expect on the management journey.
"Effective management of the condition can significantly improve a dog’s quality of life and prevents the development of other, potentially life-threatening conditions, for which treatment can be intensive and costly."
The website also has a Frequently Asked Questions section and an interactive log book for owners to fill in which can also be emailed to their veterinary surgeon to assist in tracking the dogs’ progress and ensure that treatment is at its optimal level.
For more information, visit www.hypothyroiddog.com
Zoetis has launched Suvaxyn Parvo/E, a combined vaccine which it says provides the earliest protection of gilts against parvovirus and erysipelas.
Parvovirus and erysipelas infections occur primarily in gilts and sows, negatively impacting their reproductive success and the health of their litters - inevitably reducing profitability.
Nigel Lodge, National Veterinary Manager for Zoetis, said: "The combined vaccine will help ensure the health of gilts and sows is not affected by these two infections which are widespread in the pig herd.
"Suvaxyn® Parvo/E gives the earliest protection so that the ability to vaccinate gilts at five months of age will help ensure a good start to their reproductive life. Up to half of all pigs may be carriers of erysipelas and importantly the vaccine has licensed efficacy against both Erysipelothrix serotypes 1 and 2.
"This brings another vaccine to our portfolio, making it one of the largest in the pig sector and confirming the ongoing commitment of Zoetis to the health and welfare of pigs."
Suvaxyn® Parvo/E is an inactivated combination vaccine approved for immunising gilts and sows to prevent reproductive disorders caused by porcine parvovirus and reduce clinical signs caused by Erysipelothrix rhusiopathiae.
Primary vaccination is recommended from five months of age, with two injections given three to four weeks apart, ensuring the second dose occurs at least four weeks before mating. Revaccination should take place three to four weeks before each subsequent mating.
The vaccine comes in 10-dose and 2 X 25-dose packs. For more information, contact your Zoetis Pig Key Account Manager.
Last year Petplan received over 31,000 nominations across the five award categories: Practice of the Year, Vet of the Year, Vet Nurse of the Year, Practice Manager of the Year and Practice Support Staff of the Year.
The awards are judged by an independent panel which narrows the field to three finalists in each category, who are then invited to attend the awards ceremony.
The judges are looking for examples of exceptional levels of animal care, building and sustaining great relationships with colleagues and pet owners, and those who have gone above and beyond the call of duty.
James Barnes, Head of Sales & Partnerships at Petplan, said: “The Petplan Veterinary Awards provide the perfect opportunity to say thank you for the exceptional work carried out by members of the veterinary profession, whatever their field and wherever they’re based. The Petplan Vet Awards provide a great opportunity for both clients and colleagues to recognise the dedication and talent of veterinary professionals, teams and practices, right across the UK and say a particular thank you to those who have kept up the exceptional level of care even in the midst of a global crisis."
To nominate a colleague or your practice, visit www.petplan.co.uk before nominations close on 10th January 2022.
The allied professionals that the BVA says should be led by veterinary surgeons include: Registered Veterinary Nurses (RVNs), Official Auxiliaries/ Meat Hygiene Inspectors, embryo transfer technicians, equine dental technicians, foot trimmers, farriers, hydrotherapists, animal behaviourists and veterinary physiotherapists.
To clarify where the responsibility for a patient sits and how it is shared between veterinary surgeons and allied professionals, the new policy statement also calls for:
The regulation of allied professionals to include mandatory veterinary diagnosis and oversight and appropriate access to veterinary records as pre-requisites before treatment;
Clarity on the delegation of duties for RVNs under Schedule 3 of the Veterinary Surgeons Act and protection of the ‘veterinary nurse’ title in legislation;
Consultation with the veterinary profession on any regulatory changes that may arise as a result of technological or other innovation.
British Veterinary Association President Simon Doherty (pictured right) said: "Against an evolving landscape, it’s essential that the veterinary profession keeps pace with change and addresses the challenges and opportunities it presents.
"Vets across sectors have always worked closely with allied professionals. The hub and spoke model acknowledges and clarifies this working relationship with clear lines of accountability and responsibility for the animals under our care. It also emphasises that vets’ right to diagnose, prescribe, and undertake surgical procedures and medical treatments must not be undermined.
"An effective and efficient vet-led team can help deliver better animal health and welfare, improved client care, and more effective use of skills within the veterinary professions. Given the ongoing workforce shortages, a strengthened veterinary workforce also has the potential to ease recruitment and retention concerns for both vets and RVNs and offer improved wellbeing.
"BVA will continue working with professional bodies and organisations to formalise the hub and spoke model, promote the value of regulation, and drive up professional standards."
Vouchers for twelve months' free access to Improve's Online Bitesize CPD series will be offered to veterinary surgeons, nurses and practice managers by their Protexin Territory Manager, based on their use of products in the Protexin range.
Online Bitesize CPD offers veterinary professionals the opportunity to meet their annual CPD requirements in short bursts of learning at a time and place to suit them. Its online modules of 20, 40 and 60 minutes cover a range of clinical topics, including cardiology, ophthalmology, small animal medicine, feline medicine and exotics.
Improve says the modules have been designed to be visually engaging, highly interactive and informative to ensure that the experience is rewarding.
James Kyffin, Veterinary Director at Protexin, said: "We are thrilled to be continuing our relationship with Improve International by offering practices access to its Online Bitesize CPD. We are passionate about education and Bitesize offers a convenient, exciting way for the profession to gain access to high quality CPD."
John Douglass at Improve International added: “We hope that veterinary professionals who have not yet experienced our training will take up the opportunity created by this association with Protexin Veterinary and learn new skills with our Online Bitesize CPD service for twelve months at no cost.
"The interactive modules we have created are led by recognised experts and will help them to refresh their knowledge, learn new skills and achieve their annual CPD points quota online at any time.”
Ms Bucur MRCVS faced three charges against her.
The first charge was that in April 2024, she wrote a prescription for 60 tablets of tramadol 50mg, indicating that it was for the treatment of an animal, when it was intended for the treatment of a human.
The second charge was that she allowed the prescription to be presented at a pharmacy and/or failed to stop that.
The third charge was that her conduct, in relation to the first two charges was dishonest, and misleading, and took place in circumstances where she was not professionally qualified to write a prescription for human use.
At the outset of the hearing, Ms Bucur admitted all the charges and the Committee accepted her admissions.
In relation to charge three, the Committee found that Ms Bucur had been aware that she should not have written the prescription, that she should not have indicated that it was for an animal, that she should not have deleted the prescription for the clinical record on the practice management system, and she should not have allowed or failed to prevent the prescription from being presented for dispensing.
The Committee therefore found all charges proved.
In terms of aggravating factors, the Committee considered that Ms Bucur’s conduct had given rise to a risk of injury because she was not professionally qualified or sufficiently informed to issue a prescription for tramadol, that she had acted recklessly with regard to the potential effects of a controlled, potentially addictive drug and that her conduct had been premeditated.
It also accepted the submission that there was an abuse of Ms Bucur’s professional position as a registered veterinary surgeon, because this had allowed her to issue a prescription.
The Committee also found that Ms Bucur’s conduct was aggravated by her having involved other persons in her misconduct, namely her partner, in an attempt to have the prescription dispensed.
The Committee noted that the charges involved findings of dishonesty, which is regarded at the higher end in terms of the spectrum of gravity of misconduct.
In mitigation, the Committee took into account that the facts proved related to a single incident of the issuing and attempted use of a prescription.
The Committee was of the view that the Ms Bucur’s conduct had failed to promote protection of public health and had breached the legislation around access to controlled drugs.
Even though this was a single incident, the Committee considered that members of the public, if aware of the facts, would be alarmed and concerned at Ms Bucur’s actions.
As a result, the profession could be brought into disrepute and public confidence in the profession undermined.
The Committee therefore found that Ms Bucur’s conduct amounted to serious professional misconduct in a professional respect.
The Committee then considered whether there were any relevant additional personal aggravating or mitigating factors.
The Committee did not find any further aggravating factors; in mitigation it noted that Ms Bucur had no previous complaints of adverse matters in her career.
The Committee accepted that Ms Bucur had made early, open and frank admissions to her conduct.
She had also offered a fulsome and genuine apology and remorse in her witness statement and in the hearing.
The Committee also accepted that she had since worked without further incident and concluded from her witness statement and evidence that she had developed full insight into her misconduct.
She was able to provide a notable number of references and testimonials which were uniform in speaking to her positive qualities as a veterinary surgeon.
The Committee was able to conclude that this has been a very serious but single lapse of judgement, and that there was a relevant context in that Ms Bucur had clearly acted out of concerns to help her father, however misguided.
There were no suggestions of harm, or risk of harm, to animals.
However, the Committee could not ignore that Ms Bucur’s misconduct had occurred in relation to a controlled drug and had contravened important protections designed to protect the public.
Neil Slater, chairing the Committee and speaking on its behalf, said: “The Committee balanced the effect that a suspension would have on Dr Bucur, by depriving her of the ability to practise for a period, with the public interest.
"However, it decided that, in the circumstances, the interests of protecting the public, including the wider public interest, outweighed Dr Bucur’s interests.
“The Committee decided that, in all the circumstances, a suspension was the appropriate and proportionate sanction.
“The Committee considered for how long the suspension should be imposed.
"It considered that the suspension was not required to allow for Dr Bucur to gain any further insight.
"It would purely be required to mark the Committee’s disapproval of Dr Bucur’s misconduct, as a signal to the public and to the profession.
"The Committee concluded that the least period required in all the circumstances is two months.
“The Committee therefore directed to the Registrar that Dr Bucur’s registration be suspended for a period of two months.”
https://www.rcvs.org.uk/concerns/disciplinary-hearings
Kellie Price, a Kent-based Registered Veterinary Nurse has been suspended from the Register for nine months by the RCVS RVN Disciplinary Committee after she admitted dishonestly creating four prescriptions, one of which was then fraudulently presented to a pharmacy.
The Committee heard that in January 2013, Miss Price, who did not attend the hearing and had no representation, had dishonestly created a prescription for two inhalers while working at a veterinary practice in Kent.
This prescription had been written and signed in the name of a locum veterinary surgeon, Cristiana Tudini MRCVS, without her knowledge or consent. The false prescription was subsequently presented to a pharmacy for dispensing.
In addition, in March 2013, Miss Price dishonestly created a further three prescriptions - one of which was written in the name of her colleague Cormac Higgins MRCVS, and two written in the name of Cristiana Tudini MRCVS without either's knowledge or consent. All four false prescriptions had been made out for Miss Price's Jack Russell terrier.
Upon discovering the false prescriptions, Mr Higgins asked Miss Price for an explanation and subsequently suspended her from her position pending further investigation. However, after being interviewed by Mr Higgins, she resigned before any in-house disciplinary hearing could take place. The allegations were then reported to both the RCVS and the police, the latter giving Miss Price a formal caution in respect of the false prescription made in January 2013.
In considering Miss Price's sanction, the RVN Disciplinary Committee took into account a number of aggravating and mitigating factors. In mitigation, it accepted Miss Price's explanation that, in the early hours of 6 January, she had suffered an asthma attack and that she had created the false prescription at work in a panic after realising her inhaler was empty and fearing a further asthma attack. The Committee also took into account a witness statement from Cormac Higgins MRCVS which described her as a "great nurse" and "good with patients and clients".
However, the Committee also considered aggravating factors including Miss Price's dishonesty and the fact that she then made further false prescriptions in March, although these were not then presented to a pharmacy.
Professor Noreen Burrows, who chaired the RVN Disciplinary Committee and spoke on its behalf, said: "The Committee is... satisfied that the admitted dishonesty amounts to disgraceful conduct in a professional respect [and] is satisfied that the respondent's conduct fell far short of the conduct to be expected of a registered veterinary nurse."
On deciding the sanction she added: "Taking into account all of the circumstances, the Committee has concluded that the suspension of the Respondent's name from the Register for a period of nine months is the proportionate sanction in this case."
The Committee's full findings and decision are available on the RCVS website (www.rcvs.org.uk/disciplinary).
60 veterinary surgeons, nurses and other team members from White Cross practices in Tividale, Guiseley, West Derby and Alvaston have formed 20 teams of three people, logging a total of 30,000 miles since the initiative was launched in February, or an average of 11,000 steps per team member per day.
James Harris MRCVS from White Cross Vets said: "We spend a lot of the day on our feet but really had no idea about the distance that we clock up. There are about 2,000 steps in a mile so we are walking more than five miles every day! We are always encouraging our clients to make sure their pets have a healthy lifestyle, so it’s great to practise what we preach.
"As well as the steps we take throughout the day many of us are also committed to sports and exercise regimes outside work and that has helped us to reach the top of the leaderboard for a few weeks. You might even find some of us marching on the spot to boost our step-counts and heart rates, so the Fitbit challenge is definitely keeping us active."
General manager Jo Jobling said: "We understand the vital importance of both physical and mental wellbeing, and our Fitbit challenge is a great way for our teams from across our 19 practices to work together to achieve a worthwhile healthy goal, as well as creating some healthy competition with colleagues in other practices. We also have an individual steppers league table which was recently topped by one of our veterinary nurses, Katie Rose from our Tividale practice. It might have helped that she completed a half marathon over that weekend though!"
Norbrook has verified that the pH of certain batches has increased over time and is out of specification.
This issue impacts the following batches:
A spokesperson said: "There has been no increased risk to animal safety identified but we take quality extremely seriously so we initiated a voluntary recall. We have informed all of the competent authorities and we are working with our distributor to advise immediate quarantine of any remaining inventory."
If you have any questions concerning the recall, contact Ms. Anita Vanderlaan Tel: +44 (0)28 3026 4435, Email: anita.vanderlaan@norbrook.co.uk
Animalcare has launched Vetaclean, a new range of disinfectants which the company says has a notably high kill activity against canine parvovirus and common feline viruses such as FIV, FeLV and FCV.
The range comprises Vetaclean Parvo Advance, a surface disinfectant-cleaner, Vetaclean enzymatic instrument detergent-cleaner, and an instrument disinfectant.
Animalcare Product Manager, Tony Liepman, said: "Veterinary nurses tell us that canine parvovirus is the most challenging and resistant pathogen they work with, and so we set this as our benchmark for the Vetaclean disinfectant products. Tested under EN protocols and having 99.99% + kill activity against parvovirus, our new disinfectants demonstrate high efficacy against a broad range of bacteria, including MRSA/MRSP, fungi, viruses, mycobacteria and spores.
"Infection control is in the spotlight at the moment, highlighted by initiatives from within and outside our industry. Firstly, the new Practice Standards Scheme - launched at the same time as our range - places great emphasis on having a rigorous biosecurity policy. This includes requirements for personal hygiene as well as cleanliness of premises and equipment. High-level decontamination of instruments and equipment is ensured through the Vetaclean two-stage process, which works with even soiled instruments or equipment, and in under 20 minutes. The products have also been designed to be suitable for use on the most specialised equipment seen in today’s practices, including flexible or rigid endoscopes, ultrasonic baths, aspirators, arthroscopes and re-processing machines.
"Importantly, the active ingredients in the Vetaclean range meet the criteria of the new EU Biocides Regulations, policed by the Health and Safety Executive in the UK, which came into effect on 1st September 2015. All products with biocidal activity now need to undergo a complex registration process, ensuring the products are not harmful to people, the environment or animals. The rigorous process may see many disinfectant manufacturers pull out of the market, resulting in less choice. Further, the Vetaclean range does not contain Poly (hexamethylene biguanide) hydrochloride (PHMB). The European Chemicals Agency (ECHA) is currently proposing that PHMB is listed as a category 2 carcinogen."
The Vetaclean Parvo Advance range includes a 1 litre lavender product in a self-dosing bottle, 5 litre apple and lemon-fragranced liquid concentrates and unfragranced large surface wipes. There are two different dilution rates: a general purpose dilution rate for most pathogens at 1:100 (10ml per litre), and a parvocidal dilution rate at 1:50 (20ml per litre). Animalcare says the alkaline-based formula ensures that the products are compatible with a wide range of materials and are non-staining. Both the enzymatic instrument cleaner and instrument disinfectant are available in 2 litre concentrates (incorporating a calibrated dosing reservoir).
The Vetaclean range is available now in wholesalers. The company has also produced a brochure Hygiene in practice, a guide to veterinary infection control from Animalcare, designed to help familiarise veterinary professionals with the principles and uses of the product range. There is also a special launch offer of Buy-4-Get-One-Free available from Animalcare representatives.
For further information, contact Animalcare on 01904 487687, or speak to your regional Animalcare representative: www.animalcare.co.uk/contact-us.
The intranasal vaccine can be administered to calves from one week old. It reduces the clinical signs of respiratory disease and viral shedding from infection with Bovine Respiratory Syncytial Virus (BRSV) and Parainfluenza-3 Virus (Pi3V).
MSD says that no other UK-licensed BRD vaccine can be administered earlier in life, and claims the vaccine delivers the fastest on-farm protection, with an onset of immunity after administration of 5 days for BRSV and 7 days for Pi3V. Duration of immunity is 12 weeks for both viruses.
MSD Animal Health livestock veterinary adviser Dr Kat Baxter-Smith said: "Having this early life calf pneumonia vaccine available in single dose vials will give farmers more practical leeway to be able to vaccinate vulnerable young calves from as young as a week of age, rather than delaying administration until a batch of calves are available. We know that early-age protection of young calves through intranasal vaccination can help prevent pneumonia and positively impact a beef or dairy calf’s productive future".
The new single dose vials are supplied in packs of five, complementing the five dose vials already available.
For further information, contact your MSD account manager.
Ficoxil contains the active ingredient firocoxib, an NSAID from the coxib class, known for its analgesic, anti-inflammatory, and antipyretic properties.
Ficoxil is available in two strengths, 57 mg and 227 mg in packs of 30.
The tablets, which are presented in presented in a divisible and blister-perforated form, are hypoallergenic, gluten-free, and come in a beef flavour of animal-free origin.
Ficoxil is available now from all major veterinary wholesalers.
https://www.fortehealthcare.com/product/ficoxil
The Health Products Regulatory Authority (HPRA) has also granted a marketing authorisation in exceptional circumstances (Article 25, 26 EU Reg 2019/6) for Bultavo 3 in Ireland.
The company says that so far, more than 40 million doses of Bultavo 3 have been distributed in Europe to help limit the spread of BTV-3.
Boehringer points to a recent field study published by the German reference laboratory Friedrich-Loeffler-Institut (FLI), which showed that vaccination of sheep and cattle with Bultavo 3 induces immunity against the virus1.
According to the study, animals vaccinated with Bultavo 3 consistently showed evidence of a protective antibody response to BTV-3, although animals vaccinated with other BTV-3 vaccines did not1.
Boehringer says it is now compiling the data needed to obtain a full marketing authorisation in accordance with Article 8 of EU Regulation 2019/6.
The RCVS Disciplinary Committee has suspended a Kent veterinary surgeon from the Register for eight months after he was found guilty of dishonest certification.
At the outset of the hearing held on 14/15 December, Takeshi Okano, of Lakeview Veterinary Centre in Deal, Kent, admitted charges that, whilst acting as Official Veterinarian, he had signed a number of certificates when he knew that did not have all the information needed to do so.
On 23 June 2009, Mr Okano had been asked to act as Official Veterinarian to examine four horses and sign the certificates necessary for their export to the USA. The certificates required Mr Okano to certify he had received a written declaration from the owners that the animals had been in the UK for 60 days previously. Mr Okano also signed certificates indicating that the horses had only been in France, Ireland, or the UK for the same 60-day period. Despite having received no such declarations, and having no information whatsoever of where the horses had been, Mr Okano signed the certificates. At the hearing, no explanation for Mr Okano's actions was offered.
Mrs Beverley Cottrell, Chairman of the Disciplinary Committee said: "The validity of any certificate is an integral part of the system relating to the export or import of animals. At Section G of the RCVS Guide to Professional Conduct, emphasis is given to the importance of certification, the importance of the signature and the guidance issued by DEFRA. These provisions are well known to the profession."
The Committee was satisfied that Mr Okano's actions in signing the certificates without the owners' declarations amounted to a serious departure from professional standards. In reaching a decision on sanction, it considered that, whilst a reprimand or warning would not be appropriate, neither would removing Mr Okano's name from the Register be proportionate, or necessary either in the public interest or to protect animals.
"Mr Okano is a young veterinary surgeon at the start of his career, who from the outset admitted his actions," said Mrs Cottrell noting that the testimonials from veterinary surgeons, veterinary nurses and clients, and his record of Continuing Professional Development demonstrated his commitment to high standards within the profession. "In reaching this decision, we have paid particular regard to the fact the false certification was neither persistent nor concealed, nor was he a senior veterinary surgeon."
The Committee directed Mr Okano's name be suspended from the Register for eight months.
All jobs posted on VetNurse.co.uk are valid for 60 days (double that normally offered elsewhere). They are also emailed automatically to any subscribers with matching search criteria, fed out onto Facebook and the like, and optimised for Google For Jobs.
To post an advert for a veterinary nurse, register on www.vetnurse.co.uk, login and visit: https://www.vetnurse.co.uk/veterinary-jobs/.
Alternatively, if your practice is looking for a veterinary nurse, do share this with the practice owner or manager.
The company has completed a health hazard assessment which concluded that any risk to animal and human health is likely to be low and no greater than expected for this product under normal conditions, as described on the product labelling.
The recall is for the following batches only:
Batch Numbers:
0265-900302-900246-900112-900295-909053-919103-91
Norbrook Laboratories Ltd is contacting veterinary surgeons to examine inventory immediately and quarantine products subject to this recall.
For further information, contact Gary Mckee on +44 2830 264435 or email gary.mckee@norbrook.co.uk
MSD says the new license claim means the vaccine combines the broadest calf scour protection available with unique user convenience.
MSD Animal Health livestock veterinary adviser Dr Kat Baxter-Smith said: “When correctly administered as a single 2ml intramuscular dose to pregnant cattle 12-3 weeks prior to calving, Bovilis Rotavec Corona boosts antibodies in colostrum for rotavirus, coronavirus and now both E.coli F5 (K99) and F41.
"Calves gain protection against these infectious scour pathogens by drinking the fortified colostrum from their vaccinated mothers.
“Bovilis Rotavec Corona also contains the most prevalent rotavirus strain in Europe2, which minimises the chances of a calf scour protection breakdown due to differences between vaccine antigens and the ubiquitous antigens on farm3.”
Kat added: "Vet, RAMA and farmer feedback suggests the wide vaccination window (12-3 weeks pre-calving) and the fact that an opened bottle of vaccine lasts for up to 28 days are particularly useful practical benefits in a mix of both dairy and beef suckler systems.”
Bovilis Rotavec Corona is available in 5, 20 and 50-dose packs from both veterinary professionals and the agricultural merchant trade.
References
Dechra Veterinary Products has introduced two additional new products to its Veterinary Essentials range: Alvegesic vet and Clavudale.
Alvegesic vet contains butorphanol, a well-known and widely used drug for sedation, anaesthesia and analgesia in both dogs and cats. In horses, Alvegesic vet is indicated for analgesia and sedation.
Alvegesic vet is available in 10ml multidose vials and is licensed for administration by intravenous, intramuscular or subcutaneous routes, depending on indication, in both cats and dogs.
The other new addition to the Veterinary Essentials range is Clavudale, which contains the broad spectrum antibiotic amoxicillin, potentiated with clavulanic acid. Clavudale is bactericidal, active against a wide variety of bacterial organisms, including gram-positives and gram-negatives.
Clavudale is effective in treating a wide range of bacterial diseases of cats and dogs. These include: skin disease; soft tissue infections; dental infections; urinary tract infections; respiratory disease and enteritis. Clavudale is supplied in boxes of 24 tablets, with 4 blister strips of six tablets.
Further information on Alvegesic vet and Clavudale is available by calling Liz Rawlings at Dechra on 01743 441 632 or visiting www.dechra.com
The RCVS Disciplinary Committee has directed that a veterinary surgeon from Berkshire be removed from the Register, following his administration of a prohibited substance to a racehorse and his subsequent attempts to conceal his actions.
At a six-day hearing that concluded yesterday, James Main, a partner in the O'Gorman, Slater, Main & Partners veterinary practice in Newbury, and former lead veterinary surgeon to racehorse trainer Nicky Henderson, faced four charges of serious professional misconduct concerning his treatment of Moonlit Path, a six-year-old mare owned by The Queen.
Three of the charges related to Mr Main breaching British Horseracing Authority (BHA) rules by injecting Moonlit Path with tranexamic acid (TA) on the day she was due to race; the fourth charge related to his dishonest concealment of this treatment in his practice clinical records. Nicky Henderson had himself faced a BHA Inquiry into this case in 2009 and subsequently been sanctioned.
The Committee heard that on 18 February 2009, Mr Henderson's yard requested a veterinary surgeon attend Moonlit Path to administer an injection of Dycenene the following morning. The injection was requested as the mare was prone to exercise-induced pulmonary haemorrhage. Mr Main attended on the morning of 19 February and injected the horse with intravenous tranexamic acid. Moonlit Path raced at Huntingdon later that day, along with the eventual winner, and favourite, Ravello Bay - another horse trained by Mr Henderson. Moonlit Path finished sixth and a urine sample taken from her after the race tested positive for TA.
Of the four charges, Mr Main admitted injecting Moonlit Path with TA on the day she was due to race when he knew this breached the BHA's rule prohibiting any substance other than the horse's usual feed and water being given on race day. However, Mr Main denied knowing that, if tested, a horse would test positive for TA (thereby imposing a strict liability on the trainer); he denied administering a prohibited substance to a horse with the intention to affect that horse's racing performance; and, he denied dishonestly concealing the TA injection by omitting it from his clinical records and referring to it as a 'pre-race check'.
The Committee heard and carefully considered evidence from Mr Henderson and his employees, from BHA investigating officers and its Director of Equine Science and Welfare, from an expert equine physiologist and from Mr Main himself. In its findings, the Committee stated it was "unimpressed by Mr Henderson's evidence and surprised by his apparent lack of knowledge of the rules of racing".
Whilst the Committee accepted Mr Main believed at the time that Moonlit Path would not test positive for TA, it considered he failed to fully inform himself of the medicinal product he was using; especially so as TA does not possess a Marketing Authorisation as a veterinary medicinal product. In so doing, he did not meet his professional obligation to provide Mr Henderson with the information and advice he needed.
The Committee concluded that TA was a prohibited substance and, whilst accepting that Mr Main's concern had solely been for Moonlit Path's welfare, he had actually breached BHA rules by affecting her performance through administering such a substance.
Finally, the Committee found that Mr Main had deliberately concealed the TA injection to Moonlit Path by describing it in his notes as a 'pre-race check' - a protocol developed over several years between the practice and Mr Henderson. Such inaccurate clinical records were in breach of the RCVS Guide to Professional Conduct and led the Committee to conclude he had acted dishonestly. The Committee also found Mr Main "did not act with candour" by claiming to have administered the TA injection the day before the race. On questioning by the Legal Assessor, however, he admitted that he had known that Moonlit Path was racing the same day that he administered the injection.
Professor Sheila Crispin, chairing the Committee, said: "[We] regard it as wholly unacceptable practice that a veterinary surgeon should be party to serious breaches of rules of another regulatory body in the field of animal welfare ... and which go to the very integrity of racing.
"Whilst the findings relate to a single incident, [we] are satisfied that Mr Main's actions amounted to pre-meditated misconduct ... It is highly relevant that Mr Main held positions of responsibility within the racing industry where he was required to uphold the rules and standards of the profession," she added.
Noting Mr Main's "long and hitherto unblemished career as a highly respected equine veterinary surgeon", the Committee accepted Mr Main's evidence that the reason for the administration of tranexamic acid was solely his concern about the welfare of the horse. Nevertheless, it found his evidence was "evasive, lacking in candour and on some aspects of the case his evidence was untrue".
Professor Crispin concluded: "...proven dishonesty has been held to come at the top end of the spectrum of gravity of disgraceful conduct in a professional respect ... Having considered carefully all the mitigation put forward on Mr Main's behalf, [we] have concluded that Mr Main's behaviour was wholly unacceptable and so serious that removal of his name from the Register is required."
Barclaycard has launched Paywag, a new NFC payment system for dogs.
Installed in a specially designed dog collar, the new system allows dogs to make payments up to £5.00 in value in selected pet stores and veterinary practices.